CRANBURY, N.J.--(BUSINESS WIRE)--VaxInnate Corporation, a biotechnology company pioneering breakthrough technology to develop novel seasonal and pandemic influenza vaccines, will present Phase I data demonstrating that its universal influenza vaccine candidate was safe and immunogenic at the 48th ICAAC/46th IDSA meeting in Washington, DC this month.
